Abstract
Protein-protein interactions (PPIs) can be useful targets for different pathologies. In fact controlling a function or attempting to repair an anomaly often means interfering with the cross-talk among different proteins. In order to have a general view of these cross-talks, Molecular Interaction Maps (MIMs) are used, organizing the enormous available information that is added every day and trying to understand the most suitable and accurate targets for any specific cell alteration. In this paper the c-Myc protein is taken as an example to explain the use of a map. The discovery of a peptidomimetic antagonist of c-Myc, active against proliferation of cancer cell lines, is reported and a possible mechanism of action is explained. To interfere with a specific protein-protein contact, a good starting point can be to consider a protein entity. Because the interaction between two proteins is normally characterized by a wide zone of contact, relative large inhibitors could be more convenient in the first approaches. Therefore, peptides mimicking the interacting zone can be considered as potential leads in the rational design of effective molecules. Here different examples of peptides as protein-protein interaction inhibitors are reported.
Keywords: Protein-protein interactions (PPIs), molecular interaction maps (MIMs), peptides, c-Myc
Current Topics in Medicinal Chemistry
Title: Interfering with Protein-Protein Contact: Molecular Interaction Maps and Peptide Modulators
Volume: 7 Issue: 1
Author(s): Erika Nieddu and Stefania Pasa
Affiliation:
Keywords: Protein-protein interactions (PPIs), molecular interaction maps (MIMs), peptides, c-Myc
Abstract: Protein-protein interactions (PPIs) can be useful targets for different pathologies. In fact controlling a function or attempting to repair an anomaly often means interfering with the cross-talk among different proteins. In order to have a general view of these cross-talks, Molecular Interaction Maps (MIMs) are used, organizing the enormous available information that is added every day and trying to understand the most suitable and accurate targets for any specific cell alteration. In this paper the c-Myc protein is taken as an example to explain the use of a map. The discovery of a peptidomimetic antagonist of c-Myc, active against proliferation of cancer cell lines, is reported and a possible mechanism of action is explained. To interfere with a specific protein-protein contact, a good starting point can be to consider a protein entity. Because the interaction between two proteins is normally characterized by a wide zone of contact, relative large inhibitors could be more convenient in the first approaches. Therefore, peptides mimicking the interacting zone can be considered as potential leads in the rational design of effective molecules. Here different examples of peptides as protein-protein interaction inhibitors are reported.
Export Options
About this article
Cite this article as:
Nieddu Erika and Pasa Stefania, Interfering with Protein-Protein Contact: Molecular Interaction Maps and Peptide Modulators, Current Topics in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/156802607779318271
DOI https://dx.doi.org/10.2174/156802607779318271 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and Hepatology: from Basic Research to Clinical Applications)
Current Stem Cell Research & Therapy Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Molecular Mechanisms of PPAR-γ Governing MSC Osteogenic and Adipogenic Differentiation
Current Stem Cell Research & Therapy Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry Small Molecule Antagonists of the Corticotropin Releasing Factor (CRF)Receptor: Recent Medicinal Chemistry Developments
Current Topics in Medicinal Chemistry Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Current Cancer Therapy Reviews Advances in the Pharmacologic Treatment of Hepatocellular Carcinoma
Current Clinical Pharmacology Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets The Integrative Network of Gene Expression, MicroRNA, Methylation and Copy Number Variation in Colon and Rectal Cancer
Current Bioinformatics Bladder Cancer: Update on Risk Factors, Molecular and Ultrastructural Patterns
Current Medicinal Chemistry Phosphopeptides - Chemical Synthesis, Analysis, Outlook and Limitations.
Current Organic Chemistry Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Viral Elements Sense Tumorigenic Processes:Approaching Selective Cancer Therapy
Mini-Reviews in Medicinal Chemistry MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Back Pain in Children and Adolescents: Etiology, Clinical Approach and Treatment
Current Pediatric Reviews Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism